Physician profile
David A Huff
NPI 1568491397
$1,202.09
in general payments reported to CMS, 2019-2025
14 companies · $33.30 in 2025
The $33.30 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $541 · 2020: $207 · 2021: $146 · 2022: $275 · 2025: $33.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $33.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $33.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $360.69 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $213.95 | 2019-2021 | |
| Amgen INC. | $101.45 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $94.02 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $67.36 | 2019-2021 | |
| Abbvie INC. | $61.38 | 2022 | |
| Novo Nordisk INC | $61.19 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $50.65 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $48.48 | 2022 | |
| Merck Sharp & Dohme LLC | $44.19 | 2019 | |
| Glaxosmithkline, LLC. | $43.33 | 2019-2020 | |
| Amarin Pharma, INC. | $27.72 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.20 | 2019 | |
| Supernus Pharmaceuticals, INC. | $12.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Huff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.